[\'Department of Surgery, Keck Medical Center, University of Southern California, Los Angeles, CA.\', \'Department of Medicine, Keck Medical Center, University of Southern California, Los Angeles, CA.\']
A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.